Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Studies demonstrated that prophylactic loperamide led to severe constipation during sacituzumab govitecan treatment. Dr. Tolaney advises reserving loperamide strictly for as-needed use, while prioritizing growth factor prophylaxis on days two through four and day eight for patients at high risk of neutropenia.

Related Insights

Clinical trials with zanidatumab revealed significant diarrhea primarily in the first cycle. The successful management strategy involves mandatory loperamide twice daily for the first seven days to improve tolerability and prevent treatment discontinuation, a crucial implementation pearl.

When combining sacituzumab govitecan (SASE) and pembrolizumab (IO), it's crucial to differentiate the cause of diarrhea. SASE-induced diarrhea is similar to standard chemotherapy, while IO-induced diarrhea often presents with bloody stools and severe abdominal cramping.

Given that diarrhea from Capivasertib has a rapid onset within 12 days, clinicians should consider prophylactic loperamide. This proactive approach, especially for patients with pre-existing bowel issues, can help them tolerate the therapy from the start, rather than waiting for symptoms to appear.

Initial concerns about severe diarrhea with sacituzumab govitecan are now less relevant due to improved management. Prophylactic use of strong antiemetic regimens often causes constipation, effectively preventing diarrhea and dramatically improving the drug's tolerability based on clinical experience.

To manage the high risk of neutropenia with sacituzumab govitecan, prophylactic growth factor (G-CSF) use is becoming standard clinical practice. This is particularly true after the Day 8 administration. For some populations, like Asian patients, it is considered mandatory from the start, sometimes with a dose reduction.

The HORIZON-GEA-01 trial for zanidatumab in gastric cancer mandated prophylactic loperamide (4mg BID) for all patients. This was necessary to manage the high rates of diarrhea (up to 80% of patients), a significant GI toxicity associated with the drug's mechanism of action.

Prophylactic G-CSF is used with sacituzumab govitecan not only to prevent febrile neutropenia but for practical reasons. It helps ensure patients' blood counts recover for their Day 8 dose, preventing treatment delays and simplifying scheduling for busy infusion centers.

The zanidatamab triplet regimen causes severe diarrhea in 25% of patients. Management requires mandatory prophylactic loperamide for the first seven days. Diarrhea onset often coincides with the end of prophylaxis (day 7-8), highlighting the need for proactive communication and potential continuation of loperamide to maintain patients on therapy.

For patients sensitive to standard loperamide tablets who experience rebound constipation, the liquid formulation offers more flexible, precise dosing. This allows for better symptom control of diarrhea without overcorrecting and causing constipation, improving overall patient tolerance.

Real-world use of capivaseratib reveals more challenging rash and diarrhea than trial data may suggest. The speaker recommends proactive management with non-sedating antihistamines starting the day *before* therapy and prophylactic loperamide. This strategy, combined with dose reductions that don't compromise PFS, is key for patient tolerance.